Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: Prospective cohort study

BMJ (Online)

Volumn 347, Issue 7930, 2013, Pages

  Thomas, Kyla H ^a   Martin, Richard M ^a,b   Davies, Neil M ^b   Metcalfe, Chris ^a   Windmeijer, Frank ^a   Gunnell, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; VARENICLINE;

ADULT; ARTICLE; AUTOMUTILATION; CLINICAL PRACTICE; COHORT ANALYSIS; DEPRESSION; DRUG INDICATION; DRUG SAFETY; FATALITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING CESSATION PROGRAM; SUICIDE;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; BUPROPION; COHORT STUDIES; DEPRESSION; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOXALINES; RISK ASSESSMENT; RISK FACTORS; SELF-INJURIOUS BEHAVIOR; SMOKING; SMOKING CESSATION; SUICIDE; TOBACCO USE CESSATION PRODUCTS; YOUNG ADULT;

EID: 84886628339     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5704     Document Type: Article

References (46)

1. Twigg L, Moon G, Walker S. The smoking epidemic in England. Health Development Agency, 2004.
2. World Health Organisation. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco, 2011.
3. National Institute for Health and Clinical Excellence. NICE public health guidance 10. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. NICE, 2008.
4. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009;32:119-35.
5. National Institute for Health and Clinical Excellence. NICE implementation uptake report: smoking cessation drugs, 2010.
6. Dhillon S, Yang L, Curran M. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008;68:653-89. (Pubitemid 351484811)
7. Medicines and Healthcare Products Regulatory Agency. Varenicline: adverse psychiatric reactions, including depression. Drug Safety Update 2008;2:2-3.
8. US Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin and generics). FDA Drug Safety Newsletter, 2009.
9. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend 2008;98:169-78.
10. Farrell M, Howes S, Bebbington P, Brugha T, Jenkins R, Lewis G, et al. Nicotine, alcohol and drug dependence and psychiatric comorbidity: Results of a national household survey. Br J Psychiatry 2001;179:432-37. (Pubitemid 33097166)
11. Faulk K. Pfizer settles 80 percent of more than 2, 700 lawsuits claiming problems with smoking cessation drug Chantix. Birmingham News 2013 1 March 2013.
12. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330:385-8. (Pubitemid 40288822)
13. Miller M, Hemenway D, Bell NS, Yore MM, Amoroso PJ. Cigarette smoking and suicide: a prospective study of 300, 000 male active-duty Army soldiers. Am J Epidemiol 2000;151:1060-3. (Pubitemid 30489200)
14. Miller M, Hemenway D, Rimm E. Cigarettes and suicide: a prospective study of 50, 000 men. Am J Public Health 2000;90:768-73. (Pubitemid 30246381)
15. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. Plos One 2011;6:e27016.
16. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805.
17. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389-93. (Pubitemid 40288823)
18. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-9.
19. Martens EP, Pestman WR, de BA, Belitser SV, Klungel OH. Instrumental variables: application and limitations. Epidemiology 2006;17:260-7.
20. Davies NM, Davey Smith G, Windmeijer F, Martin RM. Issues in the reporting and conduct of instrumental variable studies: a systematic review. Epidemiology 2013;24:363-9.
21. Office for National Statistics. Suicide rates in the United Kingdom 2000-2009. Stat Bull 2011:1-10.
22. Linsley KR, Schapira K, Kelly TP. Open verdict v suicide-importance to research. Br J Psychiatry 2001;178:465-8.
23. Thomas KH, Davies N, Metcalfe C, Windmeijer F, Martin RM, Gunnell D. Validation of suicide and self-harm records in the Clinical Practice Research Datalink. Br J Clin Pharmacol 2013;76:145-57.
24. Setakis E, Puri S, Gallagher A, Easton S, De Vries F, Williams TJ, et al. Linking UK death certifcate data to UK primary care data (General Practice Research Database). Pharmacoepidemiol Drug Saf 2010;19:S310-1.
25. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1
26. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Statistical software components. Boston College Department of Economics, 2003.
27. Hernan M, Robins J. Instruments for causal inference: an epidemiologist's dream? Epidemiology 2006;17:360-72. (Pubitemid 44305508)
28. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol 2009;62:1226-32.
29. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006;17:268-75.
30. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol 2009;62:1233-41.
31. Davies NM, Davey Smith G, Windmeijer F, Martin RM. COX-2 selective non-steroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variables analysis. Epidemiology 2013;4:352-62.
32. Clarke PS, Windmeijer F. Instrumental variable estimators for binary outcomes. J Am Stat Assoc 2012;107:1638-52.
33. Baum CF, Schaffer ME, Stillman S. IVREG2: Stata module for extended instrumental variables/2SLS and GMM estimation. Statistical software components. Boston College Department of Economics, 2002.
34. Wooldridge JM. Econometric analysis of cross section and panel data. 2nd ed. MIT Press, 2010.
35. Angrist JD, Pischke J-S. Mostly harmless econometrics: an empiricist's companion. Princeton University Press, 2009.
36. Stock J, Yogo M, Wright J. A survey of weak instruments and weak identification in generalized method of moments. J Bus Econ Stat 2002;20:518-29.
37. Rodriguez LAG, Gutthann SP. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25.
38. Gallagher AM, Puri S, van Staa TP. Linkage of the General Practice Research Database (GPRD) with other data sources. Pharmacoepidemiol Drug Saf 2011;20:S230-1.
39. Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J 2009;6:25.
40. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009;339:b3999.
41. Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf 2011;34:763-72.
42. Kasliwal R, Wilton LV, Shakir SAW. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009;32:499-507.
43. Meyer TE, Taylor LG, Xie S, Graham DJ, Mosholder AD, Williams JR, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction 2013;108:203-10.
44. Campbell AR, Anderson KD. Mental health stability in veterans with posttraumatic stress disorder receiving varenicline. Am J Health Syst Pharm 2010;67:1832-7.
45. Martin RM, May M, Gunnell D. Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001-2004. Br J Clin Pharmacol 2006;61:224-8. (Pubitemid 43382616)
46. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103.